The FDA-approved drug irbesartan inhibits HBV-infection in HepG2 cells stably expressing sodium taurocholate co-transporting polypeptide

Antiviral Therapy

Volumn 20, Issue 8, 2015, Pages 835-842

  Ko, Chunkyu ^a   Park, Woo Jin ^a   Park, Sanghyun ^b   Kim, Seungtaek ^c   Windisch, Marc P ^b   Ryu, Wang Shick ^a  

^a Yonsei University   (South Korea)

^b Institute Pasteur Korea   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

IRBESARTAN; SODIUM BILE ACID COTRANSPORTER; VIRUS DNA; ANTIVIRUS AGENT; BIPHENYL DERIVATIVE; COTRANSPORTER; ORGANIC ANION TRANSPORTER; SODIUM-BILE ACID COTRANSPORTER; TETRAZOLE DERIVATIVE;

ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DNA REPLICATION; DRUG APPROVAL; DRUG DETERMINATION; DRUG EFFECT; HEPATITIS B; HEPATITIS B VIRUS; HEPG2 CELL LINE; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS ENTRY; CELL CULTURE; CELL LINE; DRUG EFFECTS; GENE EXPRESSION; GENETICS; HEP-G2 CELL LINE; HUMAN; IC50; MICROBIAL SENSITIVITY TEST; VIRUS REPLICATION;

ANTIVIRAL AGENTS; BIPHENYL COMPOUNDS; CELL LINE; CELLS, CULTURED; DNA, VIRAL; GENE EXPRESSION; HEP G2 CELLS; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; INHIBITORY CONCENTRATION 50; MICROBIAL SENSITIVITY TESTS; ORGANIC ANION TRANSPORTERS, SODIUM-DEPENDENT; SYMPORTERS; TETRAZOLES; VIRUS REPLICATION;

EID: 84975139885     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2965     Document Type: Article

References (27)

1. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterol 2012; 142:1264-1273.
2. Zoulim F. Are novel combination therapies needed for chronic hepatitis B? Antiviral Res 2012; 96:256-259.
3. Gish R, Jia JD, Locarnini S, Zoulim F. Selection of chronic hepatitis B therapy with high barrier to resistance. Lancet Infect Dis 2012; 12:341-353.
4. Chevaliez S, Hezode C, Bahrami S, Grare M, Pawlotsky JM. Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely. J Hepatol 2013; 58:676-683.
5. Lampertico P, Liaw YF. New perspectives in the therapy of chronic hepatitis B. Gut 2012; 61 Suppl 1:i18-i24.
6. Block TM, Gish R, Guo H, et al. Chronic hepatitis B: what should be the goal for new therapies? Antiviral Res 2013; 98:27-34.
7. Urban S, Bartenschlager R, Kubitz R, Zoulim F. Strategies to inhibit entry of HBV and HDV into hepatocytes. Gastroenterology 2014; 147:48-64.
8. Gripon P, Rumin S, Urban S, et al. Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci U S A 2002; 99:15655-15660.
9. Yan H, Zhong G, Xu G, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife 2012; 1:e00049.
10. Ni Y, Lempp FA, Mehrle S, et al. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology 2014; 146:1070-1083.
11. Yan H, Peng B, He W, et al. Molecular determinants of hepatitis B and D virus entry restriction in mouse sodium taurocholate cotransporting polypeptide. J Virol 2013; 87:7977-7991.
12. Watashi K, Sluder A, Daito T, et al. Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP). Hepatology 2014; 59:1726-1737.
13. Nkongolo S, Ni Y, Lempp FA, et al. Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor. J Hepatol 2014; 60:723-731.
14. Lucifora J, Esser K, Protzer U. Ezetimibe blocks hepatitis B virus infection after virus uptake into hepatocytes. Antiviral Res 2013; 97:195-197.
15. Dong Z, Ekins S, Polli JE. Structure-activity relationship for FDA approved drugs as inhibitors of the human sodium taurocholate cotransporting polypeptide (NTCP). Mol Pharm 2013; 10:1008-1019.
16. Ladner SK, Otto MJ, Barker CS, et al. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. Antimicrob Agents Chemother 1997; 41:1715-1720.
17. Ko C, Lee S, Windisch MP, Ryu WS. DDX3 DEAD-Box RNA helicase is a host factor that restricts hepatitis B virus replication at the transcriptional level. J Virol 2014; 88:13689-13698.
18. Iwamoto M, Watashi K, Tsukuda S, et al. Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP. Biochem Biophys Res Commun 2014; 443:808-813.
19. Watashi K, Liang G, Iwamoto M, et al. Interleukin-1 and tumor necrosis factor-alpha trigger restriction of hepatitis B virus infection via a cytidine deaminase activation-induced cytidine deaminase (AID). J Biol Chem 2013; 288:31715-31727.
20. Ko C, Shin YC, Park WJ, Kim S, Kim J, Ryu WS. Residues Arg703, Asp777, and Arg781 of the RNase H domain of hepatitis B virus polymerase are critical for viral DNA synthesis. J Virol 2014; 88:154-163.
21. Kim HY, Li X, Jones CT, et al. Development of a multiplex phenotypic cell-based high throughput screening assay to identify novel hepatitis C virus antivirals. Antiviral Res 2013; 99:6-11.
22. Petersen J, Dandri M, Mier W, et al. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol 2008; 26:335-341.
23. Gripon P, Diot C, Theze N, et al. Hepatitis B virus infection of adult human hepatocytes cultured in the presence of dimethyl sulfoxide. J Virol 1988; 62:4136-4143.
24. Döring B, Lutteke T, Geyer J, Petzinger E. The SLC10 carrier family: transport functions and molecular structure. Curr Top Membr 2012; 70:105-168.
25. Yan H, Peng B, Liu Y, et al. Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide. J Virol 2014; 88:3273-3284.
26. König A, Doring B, Mohr C, Geipel A, Geyer J, Glebe D. Kinetics of the bile acid transporter and hepatitis B virus receptor Na+/taurocholate cotransporting polypeptide (NTCP) in hepatocytes. J Hepatol 2014; 61:867-875.
27. Blanchet M, Sureau C, Labonte P. Use of FDA approved therapeutics with hNTCP metabolic inhibitory properties to impair the HDV lifecycle. Antiviral Res 2014; 106:111-115.